Physicians' Academy for Cardiovascular Education

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield - London, UK

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

How to manage DOAC-related bleeding

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Statin-associated muscle symptoms: real or nocebo effect?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

The ORBITA trial: is PCI beneficial in stable angina patients?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. William Boden, Boston, MA, USA

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Mutated bone marrow stem cells may link aging, cancer and atherosclerosis

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - Prof. Peter Libby, Boston, MA, USA

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

BP response to exercise is exaggerated in hypertensives with controlled resting BP

Literature - June 20, 2018 - Chant B, et al. - Hypertension 2018

BP responses to exercise are similar in treated–controlled, treated-uncontrolled, and untreated hypertensives but higher compared with normotensives.

Severe hypoglycemia associated with increased risk of CV events and mortality

Literature - June 19, 2018 - Zinman B, et al. - Diabetes Care 2018
In the LEADER trial, patients with severe hypoglycemia episodes had a higher risk of CV events and mortality compared with patients without severe hypoglycemia, independent of treatment group.

In the LEADER trial, patients with severe hypoglycemia episodes had a higher risk of CV events and mortality compared with patients without severe hypoglycemia, independent of treatment group.

Longer exposure to hypertension in mid-life increases risk of dementia

Literature - June 19, 2018 - Abell JG et al. - Eur Heart J 2018
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension

Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension

Importance of hypertension in CVD prevention

Clinical updates in management of cardiovascular risk (3/4)

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK
Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.

Clinical updates in management of cardiovascular risk Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.

Translation of novel approaches in CVD & diabetes to clinical practice

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

Certain reproductive factors may increase future CV risk

Literature - June 18, 2018 - Peters SAE, and Woodward M. - Heart 2018

Several reproductive factors, including early menarche, a history of miscarriage or hysterectomy, earlier age at first birth, or an early menopause, were associated with an increased CV risk in later life.

Direct thrombin inhibitor reduces vascular complications in patients with myocardial injury after non-cardiac surgery

Literature - June 18, 2018 - Devereaux PJ, et al. - The Lancet 2018
Dabigatran therapy was associated with a lower risk of major vascular complications without an increase in major bleeding in patients with myocardial injury after non-cardiac surgery.

Dabigatran therapy was associated with a lower risk of major vascular complications without an increase in major bleeding in patients with myocardial injury after non-cardiac surgery.

Initiation of SGLT2i therapy associated with decreased CV outcomes outside the US and Europe

Literature - June 14, 2018 - Kosiborod M, et al. - J Am Coll Cardiol 2018

In a pooled analysis of databases of 6 different countries, the initiation of SGLT2i was associated with lower risks of CV outcomes, as compared with other glucose-lowering drugs.

First messages from the 2018 ESC/ESH Guidelines for treatment of hypertension

News - June 14, 2018

Before publication later this year, a first look at the new 2018 ESC/ESH Guidelines of hypertension was presented. One of the key messages was the unchanged definition of hypertension of BP >140/90 mmHg.

Obesity associated with high CV risk even in the absence of metabolic abnormalities

Literature - June 13, 2018 - Eckel N, et al. - Lancet Diab Endocrin 2018
CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

No sign of treatment-induced cardiotoxicity in breast cancer patients

Literature - June 13, 2018 - Weberpals J, et al. - Eur Heart J 2018

In breast cancer patients treated with radiotherapy or chemotherapy, the heart-specific mortality was not increased compared with the general female population.

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands
Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.

Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.